{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:48:31Z","timestamp":1783360111105,"version":"3.54.6"},"update-to":[{"DOI":"10.1002\/14651858.cd006643.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000}}],"reference-count":38,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006643.pub3","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T14:24:41Z","timestamp":1263824681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Interferon Beta for Primary Progressive Multiple Sclerosis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Juan Ignacio","family":"Rojas","sequence":"first","affiliation":[{"name":"Hospital Italiano Buenos Aires; Neurology Department; Gascon 450 Buenos Aires Buenos Aires Argentina 1411"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Romano","sequence":"additional","affiliation":[{"name":"Hospital Italiano Buenos Aires; Neurology Department; Gascon 450 CABA (Ciudad Autonoma de Buenos Aires) Buenos Aires Argentina 1181"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Ciapponi","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires; Family and Preventive Medicine Division; Independencia 1253 PB 'A' Buenos Aires Capital Federal Argentina 1099"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[{"name":"Hospital Italiano Buenos Aires; Neurology Department; Gascon 450 Buenos Aires Buenos Aires Argentina 1411"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Cristiano","sequence":"additional","affiliation":[{"name":"Hospital Italiano Buenos Aires; Neurology Department; Gascon 450 Buenos Aires Buenos Aires Argentina 1411"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"10.1002\/14651858.CD006643.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","article-title":"Interferon beta-1a in primary progressive MS","volume":"60(1)","author":"Leary","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Leary SM Thompson AJ The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis J Neurol Neurosurg Psychiatry 2004 508 9","DOI":"10.1136\/jnnp.2003.018598"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Miller DH Leary SM Thompson AJ Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis Multiple sclerosis (Houndmills, Basingstoke, England) 2004 S56 7","DOI":"10.1177\/135245850401000109"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0004|cit4","first-page":"S62","article-title":"Overview of European pilot study of interferon B-1b in primary progressive multiple sclerosis","volume":"10 suppl.1","author":"Montalban","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD006643.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/jnnp.2003.010090","article-title":"Multicentre randomised double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis","volume":"75","author":"Andersen","year":"2004","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006643.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.59.5.679","article-title":"Benefit of Interferon beta-1a on MSFC progression in secondary progressive MS.","volume":"59","author":"Cohen","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006643.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon (beta)-1a dose response in relapsing-remitting MS: The OWIMS Study","volume":"53","author":"Ebers","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006643.pub3-BIB0008|cit8","first-page":"1491","article-title":"Placebo controlled multicentre randomised trial of interferon B-1b in treatment of secondary progressive multiple sclerosis","volume":"352","author":"European Study Group on Interferon B-1b in Secondary Progressive MS","year":"1998","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006643.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular Interferon beta-1a for Disease Progression in Relapsing Multiple Sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD006643.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1-b in Secondary Progressive MS. Results from a 3-year controlled study. The North American Study Group on Interferon beta-1-b in Secondary Progressive MS","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomized double-blind placebo-controlled study of Interferon B-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"PRISMS (Prevention of Relapses and disability by Interferon B-1a subcutaneously in Multiple Sclerosis) Study group","year":"1998","journal-title":"The Lancet"},{"issue":"11","key":"10.1002\/14651858.CD006643.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group","volume":"56","author":"Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006643.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/WNL.51.6.1720","article-title":"Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b","volume":"51","author":"Bramanti","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Clerico M Faggiano F Palace J Rice G Tintor\u00e8 M Durelli L Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis Cochrane Database of Systematic Reviews 2008 10.1002\/14651858.CD005278.pub3","DOI":"10.1002\/14651858.CD005278.pub3"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in Meta-analysis detected by a simple, graphical test","volume":"315(7109)","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS","volume":"352","author":"Kappos","year":"1998","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0019|cit19","article-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. [Updated May 2005]","volume-title":"The Cochrane Library","volume":"Issue 3,","author":"Higgins","year":"2005"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"The IFNB Multiple Sclerosis Group","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awh721","article-title":"The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease","volume":"129","author":"Kremenchutzky","year":"2006","journal-title":"Brain"},{"issue":"11","key":"10.1002\/14651858.CD006643.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-200519050-00001","article-title":"Primary progressive multiple sclerosis: current and future treatment options","volume":"19","author":"Leary","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch6"},{"issue":"4","key":"10.1002\/14651858.CD006643.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. Natinal Multiple Sclerosis Society (USA) Advisory Committe on Cinical Tials of new agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Miller DH Leary SM Primary-progressive multiple sclerosis Lancet neurology 2007 903 12","DOI":"10.1016\/S1474-4422(07)70243-0"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Montalban X Primary progressive multiple sclerosis Current opinion in neurology 2005 261 6","DOI":"10.1097\/01.wco.0000169742.37159.e9"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39(3)","author":"Jacobs","year":"1996","journal-title":"Annals of neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in Secondary Progressive MS: Results from a 3 year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006643.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006643.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archneur.58.8.1297","article-title":"The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta","volume":"58","author":"Rice","year":"2001","journal-title":"Archives of neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.52.4.839","article-title":"Primary and transitional MS: a clinical and MRI cross-sectional study","volume":"52(4)","author":"Stevenson","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/120.6.1085","article-title":"Primary progressive multiple sclerosis","volume":"120(6)","author":"Thompson","year":"1997","journal-title":"Brain"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/1531-8249(200006)47:6<831::AID-ANA21>3.0.CO;2-H","article-title":"Diagnostic criteria for PPMS: a position paper","volume":"47","author":"Thompson","year":"2000","journal-title":"Annals of neurology"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0022-510X(86)90138-3","article-title":"Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?","volume":"76","author":"Lambalgen","year":"1986","journal-title":"Journal of neurological sciences"},{"key":"10.1002\/14651858.CD006643.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of life research"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006643.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:08:00Z","timestamp":1779242880000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006643.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006643.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}